Side-by-side · Research reference
LivagenvsTeriparatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/32 cited
BFDA-ApprovedHUMAN-REVIEWED10/62 cited
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
Teriparatide
PTH (1-34) Fragment · FDA-Approved
SQ · Thigh/Abdomen · Once Daily
01Mechanism of Action
Parameter
Livagen
Teriparatide
Primary target
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026
Pathway
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity
Downstream effect
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites
Feedback intact?
—
Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption
Origin
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH
Antibody development
—
—
02Dosage Protocols
Parameter
Livagen
Teriparatide
Animal dose (oral)
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
—
Duration (experimental)
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
—
Route
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
Subcutaneous (thigh or abdomen)
Evidence basis
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
RCT / FDA-approved
Human data
None in provided literature
—
Standard dose (osteoporosis)
—
20 mcg / day
FDA-approved regimen for severe osteoporosis.
Frequency
—
Once daily
Intermittent administration preserves anabolic effect.
Maximum duration
—
24 months lifetime
Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.
Hypoparathyroidism dose
—
20 mcg / day
Used off-label for chronic hypoparathyroidism.
Pelvic fragility fractures
—
20 mcg / day × 8-12 weeks
Accelerates fracture healing; reduces time to union.Crooks 2026
Timing
—
Morning or evening (flexible)
Storage
—
Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use
Pharmacogenetics
—
ALDH2 polymorphisms may influence BMD responseObara 2026
ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026
03Metabolic / Fat Loss Evidence
Parameter
Livagen
Teriparatide
Fat loss application
—
None — teriparatide is a bone anabolic agent without direct lipolytic activity
04Side Effects & Safety
Parameter
Livagen
Teriparatide
Reported adverse effects
None documented in animal studies
—
Human safety data
No human trials in provided literature
—
Hypercalcemia
—
Transient serum calcium elevation 4-6 hours post-injection
Monitor serum calcium; usually asymptomatic.
Orthostatic hypotension
—
Dizziness, lightheadedness within hours of injection
Nausea
—
Common, usually mild and transient
Leg cramps / Arthralgia
—
Musculoskeletal pain reported in clinical trials
Hypercalciuria
—
Increased urinary calcium excretion; monitor for nephrolithiasis risk
Osteosarcoma (black box warning)
—
Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation
Injection site reaction
—
Erythema, bruising, pain (uncommon)
Absolute Contraindications
Livagen
—Teriparatide
- ·Paget's disease of bone (increased baseline osteosarcoma risk)
- ·Unexplained elevated alkaline phosphatase
- ·Prior skeletal radiation therapy
- ·Skeletal malignancies or bone metastases
- ·Hypercalcemic disorders (primary hyperparathyroidism)
- ·Pregnancy / lactation
Relative Contraindications
Livagen
—Teriparatide
- ·Active or recent nephrolithiasis
- ·Severe renal impairment (CKD G4-G5)
- ·Hypercalciuria without adequate monitoring
05Administration Protocol
Parameter
Livagen
Teriparatide
1. Route selection
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.
2. Timing
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.
3. Age-dependent response
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.
4. Injection technique
—
Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.
5. Monitoring
—
Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.
6. Calcium and vitamin D supplementation
—
Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.